Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr. Simona Grozinsky-Glasberg
Introduction: Paragangliomas (PGL) are a heterogeneous group of rare tumours that can express high numbers of somatostatin receptors on their cell surface and can be targeted with peptide receptor radionuclide therapy (PRRT) using the radiolabelled somatostatin analogue [lutetium-177-DOTA-Tyr3-]octreotate (177Lu-octreotate).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Daan Smit Duijzentkunst